|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,384.50 GBX | +3.01% |
|
+2.98% | -4.74% |
| 05:10pm | GSK's Blenrep Combination Therapy for Multiple Myeloma Gets Priority Review in China | MT |
| 12:31pm | AlphaValue/Baader Europe Lifts CureVac FY24 Outlook | MT |
| Capitalization | 54.84B 69.91B 66.15B 61.32B 98.83B 5,920B 109B 763B 282B 2,432B 263B 257B 10,480B | P/E ratio 2024 * |
15x | P/E ratio 2025 * | 9.5x |
|---|---|---|---|---|---|
| Enterprise value | 68.67B 87.53B 82.83B 76.78B 124B 7,412B 137B 955B 353B 3,046B 329B 321B 13,122B | EV / Sales 2024 * |
2.2x | EV / Sales 2025 * | 2.06x |
| Free-Float |
-
| Yield 2024 * |
4.49% | Yield 2025 * | 4.79% |
More valuation ratios
* Estimated data
More news
Last Transcript: GSK plc
More press releases
More news
| 1 day | +3.01% | ||
| 1 week | +2.98% | ||
| Current month | +3.48% | ||
| 1 month | -1.11% | ||
| 3 months | -16.95% | ||
| 6 months | -14.77% | ||
| Current year | -4.74% |
1 week
1 329.88
1 390.00
1 month
1 282.501 407.00
Current year
1 282.501 823.50
1 year
1 282.501 823.50
3 years
1 280.923 408.16
5 years
1 280.923 408.16
10 years
1 280.923 408.16
| Director | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 31/03/2017 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 30/04/2023 |
James Ford
CMP | Compliance Officer | - | 31/07/2018 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
BRD | Director/Board Member | 55 | 31/12/2016 |
Jesse Goodman
BRD | Director/Board Member | 72 | 31/12/2015 |
Hal Barron
BRD | Director/Board Member | 62 | 31/12/2017 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.17% | 11 M€ | +0.83% | - | |
| 3.15% | 20 M€ | +16.89% | - | |
| 2.97% | 55 M€ | +4.52% | - | |
| 2.51% | 8 M€ | +10.37% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +3.01% | +2.98% | -4.55% | -30.80% | 69.91B | ||
| -2.04% | +1.42% | +38.88% | +233.94% | 744B | ||
| -0.41% | +0.84% | +16.90% | +108.39% | 493B | ||
| +0.78% | -2.77% | -2.93% | -9.28% | 359B | ||
| +0.58% | -2.38% | +17.33% | +42.93% | 311B | ||
| +1.74% | +4.26% | +0.51% | +43.97% | 261B | ||
| +0.14% | +0.23% | +0.98% | -31.36% | 235B | ||
| +0.25% | +1.21% | +5.80% | +27.74% | 211B | ||
| -0.52% | -4.05% | +4.43% | +19.73% | 205B | ||
| +1.48% | -0.24% | +1.95% | +30.52% | 147B | ||
| Average | +0.50% | -0.40% | +7.93% | +43.58% | 303.57B | |
| Weighted average by Cap. | -0.13% | +0.54% | +14.52% | +83.62% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 31.17B 39.73B 37.6B 34.85B 56.17B 3,365B 62.18B 434B 160B 1,382B 149B 146B 5,957B | 32.32B 41.19B 38.98B 36.14B 58.24B 3,489B 64.47B 450B 166B 1,433B 155B 151B 6,176B |
| Net income | 3.67B 4.68B 4.43B 4.11B 6.62B 397B 7.33B 51.11B 18.9B 163B 17.59B 17.2B 702B | 5.81B 7.4B 7B 6.49B 10.46B 627B 11.58B 80.79B 29.87B 258B 27.8B 27.19B 1,110B |
| Net Debt | 13.82B 17.62B 16.67B 15.46B 24.91B 1,492B 27.58B 192B 71.1B 613B 66.19B 64.72B 2,642B | 11.69B 14.9B 14.1B 13.07B 21.06B 1,262B 23.32B 163B 60.12B 518B 55.97B 54.72B 2,234B |
More financial data
* Estimated data
Employees
70,212
Sector
Pharmaceuticals
Calendar
10/12/2024
- American Society of Hematology Meeting
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/12/24 | 1,382.50 p | +2.86% | 3,537,735 |
| 06/12/24 | 1,344.00 p | +0.19% | 10,897,190 |
| 05/12/24 | 1,341.50 p | -1.00% | 6,605,517 |
| 04/12/24 | 1,355.00 p | -0.95% | 14,432,390 |
| 03/12/24 | 1,368.00 p | +1.98% | 7,976,947 |
Delayed Quote London S.E., December 09, 2024 at 04:17 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
13.44GBP
Average target price
18.17GBP
Spread / Average Target
+35.23%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition